Goldman Sachs Gives Insmed Buy Rating, $188 Price Target

Goldman Sachs has initiated coverage on Insmed Inc., giving the commercial-stage biopharmaceutical company a buy rating and a price target of $188.00.

The target represents significant upside from Insmed's current stock price of $118.34, though InvestingPro analysis suggests the stock is trading above its Fair Value.

Insmed's first commercial product, Arikayce, is the first approved therapy for refractory NTM Mycobacterium avium complex lung disease and is under regulatory priority review for expansion to newly diagnosed MAC lung disease with a PDUFA date of January 28, 2027.

The company posted revenue of $1.14 billion over the last twelve months with an impressive 186% growth rate and gross profit margins exceeding 83%. Analysts anticipate continued sales growth in the current year, with 12 analysts recently revising their earnings estimates upward.